Suppr超能文献

5-羟色胺3受体

5-HT3 receptors.

作者信息

Thompson A J, Lummis S C R

机构信息

Department of Biochemistry, University of Cambridge, Cambridge CB2 1QW, UK.

出版信息

Curr Pharm Des. 2006;12(28):3615-30. doi: 10.2174/138161206778522029.

Abstract

The 5-HT(3) receptor is a member of the Cys-loop family of ligand-gated ion channels. These receptors are located in both the peripheral and central nervous systems, where functional receptors are constructed from five subunits. These subunits may be the same (homopentameric 5-HT(3A) receptors) or different (heteropentameric receptors, usually comprising of 5-HT(3A) and 5-HT(3B) receptor subunits), with the latter having a number of distinct properties. The 5-HT(3) receptor binding site is comprised of six loops from two adjacent subunits, and critical ligand binding amino acids in these loops have been largely identified. There are a range of selective agonists and antagonists for these receptors and the pharmacophore is reasonably well understood. There are also a wide range of compounds that can modulate receptor activity. Studies have suggested many diverse potential disease targets that might be amenable to alleviation by 5-HT(3) receptor selective compounds but to date only two applications have been fully realised in the clinic: the treatment of emesis and irritable-bowel syndrome.

摘要

5-羟色胺(3)受体是半胱氨酸环家族配体门控离子通道的成员。这些受体位于外周和中枢神经系统,功能性受体由五个亚基构成。这些亚基可能相同(同五聚体5-羟色胺(3A)受体)或不同(异五聚体受体,通常由5-羟色胺(3A)和5-羟色胺(3B)受体亚基组成),后者具有许多独特的特性。5-羟色胺(3)受体结合位点由两个相邻亚基的六个环组成,这些环中关键的配体结合氨基酸已基本确定。针对这些受体有一系列选择性激动剂和拮抗剂,其药效基团也得到了较好的理解。还有多种化合物可调节受体活性。研究表明,许多不同的潜在疾病靶点可能适合用5-羟色胺(3)受体选择性化合物缓解,但迄今为止,临床上仅实现了两种应用:治疗呕吐和肠易激综合征。

相似文献

1
5-HT3 receptors.
Curr Pharm Des. 2006;12(28):3615-30. doi: 10.2174/138161206778522029.
2
The 5-HT3 receptor as a therapeutic target.
Expert Opin Ther Targets. 2007 Apr;11(4):527-40. doi: 10.1517/14728222.11.4.527.
3
5-HT(3) receptors.
J Biol Chem. 2012 Nov 23;287(48):40239-45. doi: 10.1074/jbc.R112.406496. Epub 2012 Oct 4.
4
Conformational Changes in the 5-HT Receptor Extracellular Domain Measured by Voltage-Clamp Fluorometry.
Mol Pharmacol. 2019 Dec;96(6):720-734. doi: 10.1124/mol.119.116657. Epub 2019 Oct 3.
5
Computational analysis of ligand recognition sites of homo- and heteropentameric 5-HT3 receptors.
Eur J Med Chem. 2010 Nov;45(11):4746-60. doi: 10.1016/j.ejmech.2010.07.039. Epub 2010 Jul 27.
6
Importance of recognition loops B and D in the activation of human 5-HT₃ receptors by 5-HT and meta-chlorophenylbiguanide.
Neuropharmacology. 2013 Oct;73:398-403. doi: 10.1016/j.neuropharm.2013.06.017. Epub 2013 Jun 26.
9
Heterogeneity amongst 5-HT₃ receptor subunits: is this significant?
Curr Mol Med. 2011 Feb;11(1):57-68. doi: 10.2174/156652411794474392.
10
Therapeutics of 5-HT3 receptor antagonists: current uses and future directions.
Pharmacol Ther. 2011 Jun;130(3):338-47. doi: 10.1016/j.pharmthera.2011.02.003. Epub 2011 Feb 26.

引用本文的文献

2
Serotonergic Regulation in Alzheimer's Disease.
Int J Mol Sci. 2025 May 29;26(11):5218. doi: 10.3390/ijms26115218.
4
Topological segregation of stress sensors along the gut crypt-villus axis.
Nature. 2025 Apr;640(8059):732-742. doi: 10.1038/s41586-024-08581-9. Epub 2025 Feb 12.
5
Serotonin signaling to regulate energy metabolism: a gut microbiota perspective.
Life Metab. 2024 Nov 23;4(2):loae039. doi: 10.1093/lifemeta/loae039. eCollection 2025 Apr.
6
Targeting 5-HT Is a Potential Therapeutic Strategy for Neurodegenerative Diseases.
Int J Mol Sci. 2024 Dec 15;25(24):13446. doi: 10.3390/ijms252413446.
7
Quetiapine competitively inhibits 5-HT receptor-mediated currents in NCB20 neuroblastoma cells.
Korean J Physiol Pharmacol. 2025 May 1;29(3):373-384. doi: 10.4196/kjpp.24.363. Epub 2024 Dec 18.
8
Ethanol abolishes ventilatory long-term facilitation and blunts the ventilatory response to hypoxia in female rats.
Respir Physiol Neurobiol. 2025 Feb-Mar;332:104373. doi: 10.1016/j.resp.2024.104373. Epub 2024 Nov 25.
9
Haloperidol, a typical antipsychotic, inhibits 5-HT receptor-mediated currents in NCB-20 cells: a whole-cell patch-clamp study.
Korean J Physiol Pharmacol. 2025 May 1;29(3):349-358. doi: 10.4196/kjpp.24.320. Epub 2024 Nov 22.

本文引用的文献

1
A BIOCHEMICAL AND PHARMACOLOGICAL SUGGESTION ABOUT CERTAIN MENTAL DISORDERS.
Proc Natl Acad Sci U S A. 1954 Apr;40(4):228-31. doi: 10.1073/pnas.40.4.228.
2
Atomic force microscopy reveals the stoichiometry and subunit arrangement of 5-HT3 receptors.
Proc Natl Acad Sci U S A. 2005 Aug 30;102(35):12595-600. doi: 10.1073/pnas.0503253102. Epub 2005 Aug 22.
3
General anesthetic-induced channel gating enhancement of 5-hydroxytryptamine type 3 receptors depends on receptor subunit composition.
J Pharmacol Exp Ther. 2005 Nov;315(2):771-6. doi: 10.1124/jpet.105.090621. Epub 2005 Aug 4.
4
Substance abuse among patients with schizophrenia.
J Psychiatr Pract. 2002 Mar;8(2):70-80. doi: 10.1097/00131746-200203000-00003.
5
Spatial orientation of the antagonist granisetron in the ligand-binding site of the 5-HT3 receptor.
Mol Pharmacol. 2005 Aug;68(2):365-71. doi: 10.1124/mol.105.011957. Epub 2005 May 24.
9
A controlled trial of ondansetron in the pruritus of cholestasis.
Aliment Pharmacol Ther. 2005 Apr 15;21(8):1041-5. doi: 10.1111/j.1365-2036.2005.02430.x.
10
The effect of Ondansetron on memory in schizophrenic patients.
Brain Res Bull. 2005 Apr 30;65(4):291-5. doi: 10.1016/j.brainresbull.2003.09.022.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验